Moderna to Test Flu-COVID Vaccine Combo in Late-Stage Trials, Aiming for 2025 Approval

Moderna announced plans to advance a flu-COVID vaccine combination into late-stage testing following positive earlier results.

The goal is a 2-in-1 vaccine that simplifies annual shots and potentially increases vaccine uptake.

Moderna aims to get regulatory approval in 2025 if trials are successful.

Other companies like Pfizer are also developing flu-COVID vaccine combinations.

Combination vaccines bring potential benefits like improved compliance and value for healthcare systems.